Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery
- PMID: 15713945
- DOI: 10.1056/NEJMoa050330
Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery
Abstract
Background: Valdecoxib and its intravenous prodrug parecoxib are used to treat postoperative pain but may involve risk after coronary-artery bypass grafting (CABG). We conducted a randomized trial to assess the safety of these drugs after CABG.
Methods: In this randomized, double-blind study involving 10 days of treatment and 30 days of follow-up, 1671 patients were randomly assigned to receive intravenous parecoxib for at least 3 days, followed by oral valdecoxib through day 10; intravenous placebo followed by oral valdecoxib; or placebo for 10 days. All patients had access to standard opioid medications. The primary end point was the frequency of predefined adverse events, including cardiovascular events, renal failure or dysfunction, gastroduodenal ulceration, and wound-healing complications.
Results: As compared with the group given placebo alone, both the group given parecoxib and valdecoxib and the group given placebo and valdecoxib had a higher proportion of patients with at least one confirmed adverse event (7.4 percent in each of these two groups vs. 4.0 percent in the placebo group; risk ratio for each comparison, 1.9; 95 percent confidence interval, 1.1 to 3.2; P=0.02 for each comparison with the placebo group). In particular, cardiovascular events (including myocardial infarction, cardiac arrest, stroke, and pulmonary embolism) were more frequent among the patients given parecoxib and valdecoxib than among those given placebo (2.0 percent vs. 0.5 percent; risk ratio, 3.7; 95 percent confidence interval, 1.0 to 13.5; P=0.03).
Conclusions: The use of parecoxib and valdecoxib after CABG was associated with an increased incidence of cardiovascular events, arousing serious concern about the use of these drugs in such circumstances.
Copyright 2005 Massachusetts Medical Society.
Comment in
-
COX-2 inhibitors--lessons in drug safety.N Engl J Med. 2005 Mar 17;352(11):1133-5. doi: 10.1056/NEJMe058042. Epub 2005 Feb 15. N Engl J Med. 2005. PMID: 15713946 No abstract available.
-
COX-2 inhibitors--a lesson in unexpected problems.N Engl J Med. 2005 Mar 17;352(11):1131-2. doi: 10.1056/NEJMe058038. Epub 2005 Feb 15. N Engl J Med. 2005. PMID: 15713947 No abstract available.
Similar articles
-
Presurgical intravenous parecoxib sodium and follow-up oral valdecoxib for pain management after laparoscopic cholecystectomy surgery reduces opioid requirements and opioid-related adverse effects.Acta Anaesthesiol Scand. 2004 Oct;48(9):1194-207. doi: 10.1111/j.1399-6576.2004.00495.x. Acta Anaesthesiol Scand. 2004. PMID: 15352969 Clinical Trial.
-
Cardiovascular safety of the cyclooxygenase-2 selective inhibitors parecoxib and valdecoxib in the postoperative setting: an analysis of integrated data.Anesth Analg. 2009 Jan;108(1):299-307. doi: 10.1213/ane.0b013e31818ca3ac. Anesth Analg. 2009. PMID: 19095866
-
Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery.J Thorac Cardiovasc Surg. 2003 Jun;125(6):1481-92. doi: 10.1016/s0022-5223(03)00125-9. J Thorac Cardiovasc Surg. 2003. PMID: 12830070 Clinical Trial.
-
Increased risk of cardiovascular events with parecoxib/valdecoxib: a systematic review and meta-analysis.N Z Med J. 2005 Nov 25;118(1226):U1755. N Z Med J. 2005. PMID: 16311613 Review.
-
[Valdecoxib (Bextra)].Rev Med Liege. 2004 Apr;59(4):251-4. Rev Med Liege. 2004. PMID: 15182039 Review. French.
Cited by
-
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.Lancet. 2013 Aug 31;382(9894):769-79. doi: 10.1016/S0140-6736(13)60900-9. Epub 2013 May 30. Lancet. 2013. PMID: 23726390 Free PMC article.
-
National drug utilization trend of analgesics in China: an analysis of procurement data at 793 public hospitals from 2013 to 2018.J Pharm Policy Pract. 2021 May 25;14(1):45. doi: 10.1186/s40545-021-00325-8. J Pharm Policy Pract. 2021. PMID: 34034830 Free PMC article.
-
Is fluid retention a cardiovascular risk factor?Clin Hemorheol Microcirc. 2024;88(2):277-288. doi: 10.3233/CH-242128. Clin Hemorheol Microcirc. 2024. PMID: 39302357 Free PMC article. Review.
-
Modulation of p73 isoforms expression induces anti-proliferative and pro-apoptotic activity in mantle cell lymphoma independent of p53 status.Leuk Lymphoma. 2016 Dec;57(12):2874-2889. doi: 10.3109/10428194.2016.1165814. Epub 2016 Apr 13. Leuk Lymphoma. 2016. PMID: 27074052 Free PMC article.
-
Pre-emptive and preventive NSAIDs for postoperative pain in adults undergoing all types of surgery.Cochrane Database Syst Rev. 2021 Jun 14;6(6):CD012978. doi: 10.1002/14651858.CD012978.pub2. Cochrane Database Syst Rev. 2021. PMID: 34125958 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials